0000000000223341

AUTHOR

Maurizio G. Uva

showing 5 related works from this author

Enhanced depth imaging optical coherence tomography of the choroid in idiopathic macular hole: A cross-sectional prospective study.

2010

Purpose To determine the choroidal thickness in the macular area in patients with idiopathic macular hole in one eye and an unaffected fellow eye and in healthy controls. Design Cross-sectional, prospective study. Methods Twenty-two patients with a full-thickness unilateral idiopathic macular hole and 22 age- and sex-matched controls were recruited. Enhanced depth imaging optical coherence tomography images were obtained by using spectral-domain optical coherence tomography. The choroidal thickness was measured in the subfoveal area and 1000 μm and 2000 μm away from the fovea in the nasal and temporal regions. The diameter of the macular hole and the axial length were determined. Results Ch…

Malemedicine.medical_specialtygenetic structuresEye diseaseOptical coherence tomographyOphthalmologymedicineHumansProspective StudiesProspective cohort studyMacular holeAgedCross-Sectional StudieAged 80 and overmedicine.diagnostic_testbusiness.industryChoroidMiddle Agedmedicine.diseaseRetinal Perforationseye diseasesProspective StudieOphthalmologyAxial Length Eyemedicine.anatomical_structureCross-Sectional StudiesRetinal PerforationMaculopathyFemalesense organsEnhanced depth imagingChoroidbusinessTomography Optical CoherenceHumanRetinopathyAmerican journal of ophthalmology
researchProduct

DEXAMETHASONE INTRAVITREAL IMPLANT VS RANIBIZUMAB IN THE TREATMENT OF MACULAR EDEMA SECONDARY TO BRACHYTHERAPY FOR CHOROIDAL MELANOMA

2017

PURPOSE To evaluate the efficacy of an intravitreal dexamethasone (Dex) implant 0.7 mg compared with intravitreal ranibizumab (Ra) for the treatment of radiation maculopathy with macular edema secondary to plaque brachytherapy in choroidal melanoma. METHODS Eight patients were treated with intravitreal Ra, and eight patients received the Dex intravitreal implant. Visual acuity and foveal thickness were evaluated using spectral domain optical coherence tomography. RESULTS The mean calculated irradiation to the fovea and mean times from brachytherapy to maculopathy development did not differ significantly between groups. In the Ra group, a mean 7.8 ± 3.9 injections were given and the mean fol…

MaleVisual acuitygenetic structuresmedicine.medical_treatmentBrachytherapyOcular hypertensionAngiogenesis InhibitorsDrug Implant0302 clinical medicineGlucocorticoidDexamethasone Intravitreal ImplantRadiation InjurieMelanomaDrug ImplantsChoroid NeoplasmsGeneral MedicineMiddle AgedIntravitreal InjectionsDrug Therapy CombinationFemalemedicine.symptommedicine.drugAngiogenesis InhibitorHumanmedicine.medical_specialtyBrachytherapydexamethasone03 medical and health sciencesradiation maculopathyOphthalmologyRanibizumabmedicineHumanschoroidal melanomaRadiation InjuriesGlucocorticoidsMacular edemaDexamethasoneAgedRetrospective Studiesmacular edemabusiness.industryIntravitreal Injectionmedicine.diseaseeye diseasesOphthalmology030221 ophthalmology & optometryMaculopathyRanibizumabbusinessChoroid Neoplasm030217 neurology & neurosurgery
researchProduct

Molecular and clinical studies in five index cases with novel mutations in the GLA gene

2016

Fabry disease is a metabolic and lysosomal storage disorder caused by the functional defect of the α-galactosidase A enzyme; this defect is due to mutations in the GLA gene, that is composed of seven exons and is located on the long arm of the X-chromosome (Xq21–22). The enzymatic deficit is responsible for the accumulation of glycosphingolipids in lysosomes of different cellular types, mainly in those ones of vascular endothelium. It consequently causes a cellular and microvascular dysfunction. In this paper, we described five novel mutations in the GLA gene, related to absent enzymatic activity and typical manifestations of Fabry disease. We identified three mutations (c.846_847delTC, p.E…

0301 basic medicineAdultMalep.R227Pnovel moutationAdolescentc.639 + 5G > TMutation MissenseBiologyLeft ventricular hypertrophy03 medical and health sciencesExonYoung Adult0302 clinical medicineSettore BIO/13 - Biologia ApplicataGeneticsmedicinefabry; novel moutationMissense mutationAlpha-galactosidase AHumansPoint MutationCornea verticillataGenetic Predisposition to DiseaseChildfabryGLA genec.846_847delTCGeneticsAlpha-galactosidasePoint mutationFabry disease; Alpha-galactosidase A; c.846_847delTC; p.E341X; p.C382X; p.R227P; c.639 + 5G > Tp.E341XGeneral MedicineMiddle Agedmedicine.diseaseMolecular biologyFabry diseaseStop codon030104 developmental biologyp.C382Xalpha-Galactosidasebiology.proteinFabry DiseaseFemalemedicine.symptom030217 neurology & neurosurgery
researchProduct

Intravitreal dexamethasone implant for cystoid macular edema and inflammation after scleral buckling

2015

Purpose Cystoid macular edema may occur following scleral buckling and therefore deteriorate the visual outcome. Inflammation may be the major causative factor in the development of postoperative cystoid macular edema. This case demonstrates the effectiveness of a dexamethasone implant as a treatment after the onset of choroidal inflammation and cystoid macular edema 6 months following scleral buckling and having visual acuity restored. Methods A 59-year-old phakic woman treated with scleral buckling for macula-off retinal detachment presented 2 months after surgery with cystoid macular edema with choroidal inflammation. Optical coherence tomography and fluorescein angiography were performe…

medicine.medical_specialtyTriamcinolone acetonideVisual acuityChoroiditisgenetic structuresVisual AcuityTriamcinolone AcetonideDrug ImplantDexamethasoneMacular EdemaChoroiditiPostoperative ComplicationsGlucocorticoidOptical coherence tomographyOphthalmologyChoroidal inflammationMedicineHumansFluorescein AngiographyMacular edemaGlucocorticoidsDexamethasoneDrug Implantsmedicine.diagnostic_testbusiness.industryIntravitreal InjectionRetinal DetachmentRetinal detachmentGeneral MedicineIntravitreal dexamethasone implantMiddle Agedmedicine.diseaseFluorescein angiographyeye diseasesOphthalmologyScleral BucklingIntravitreal InjectionsFemalesense organsImplantPostoperative Complicationmedicine.symptombusinessCystoid macular edemaTomography Optical Coherencemedicine.drugHuman
researchProduct

Association of neovascular age-related macular degeneration with month and season of birth in Italy

2016

In order to investigate the influence of season and month of birth on the risk of neovascular age-related macular degeneration (n-AMD) in Italy, we evaluated the month birth and sex of all patients, recorded in the anti-vascular endothelial growth factor (VEGF) monitoring registry of the Italian Medicines Agency, born between 1925-1944, who received intravitreal anti-VEGF injections for n-AMD between January 1, 2013 and July 29, 2015. The numbers of all births in Italy in the same years, extracted from the Italian National Institute of Statistics, were used to calculate the expected number of n-AMD cases. Overall, 45,845 patients (19,207 men, 26,638 women) received intravitreal anti-VEGF fo…

MaleVascular Endothelial Growth Factor AAginggenetic structuresMonth of birthVEGF receptorsneovascular AMDAngiogenesis InhibitorsAptamersMacular Degeneration0302 clinical medicineSeason of birthReceptors80 and overMedicineRegistriesAged 80 and overNeovascularization PathologicbiologyVascular Endothelial Growth FactorIncidenceIncidence (epidemiology)Aptamers NucleotideBevacizumabTreatment OutcomeItalyanti-VEGFFemaleSeasonsNucleotideNeovascular age-related macular degenerationResearch Papermedicine.drugAnti-VEGF; Month of birth; Neovascular age-related macular degeneration; Neovascular AMD; Season of birth; Aged; Aged 80 and over; Angiogenesis Inhibitors; Aptamers Nucleotide; Bevacizumab; Female; Humans; Incidence; Italy; Macular Degeneration; Male; Neovascularization Pathologic; Ranibizumab; Receptors Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Registries; Treatment Outcome; Vascular Endothelial Growth Factor A; Seasons; Aging; Cell BiologySeason of birthBevacizumabRecombinant Fusion ProteinsNeovascular AMDneovascular age-related macular degeneration03 medical and health sciencesRanibizumabAge relatedHumansNeovascularizationAgedPathologicseason of birthbusiness.industrymonth of birthAnti-VEGFCell BiologyMacular degenerationmedicine.diseaseeye diseasesanti-VEGF; month of birth; neovascular AMD; neovascular age-related macular degeneration; season of birthReceptors Vascular Endothelial Growth Factor030221 ophthalmology & optometrybiology.proteinsense organsRanibizumabbusinessMonth of birth030217 neurology & neurosurgeryDemographyAging
researchProduct